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Intentional and unintentional medication nonadherence in psoriasis: the role 
of patients’ medication beliefs and habit strength 
R. Thorneloe, C.E.M. Griffiths, R. Emsley, D. Ashcroft, L. Cordingley, on behalf 
of the PSORT study group and BADBIR  
University of Manchester and Manchester Academic Health Science Centre, 
Manchester, U.K.  
Medication nonadherence is a missed opportunity for therapeutic benefit. Patients’ 
beliefs about their medication are key drivers of nonadherence; however, there is a 
lack of high‐quality data on nonadherence to systemic therapies used for psoriasis 
outside of clinical trials. As part of the Psoriasis Stratification to Optimise Relevant 
Therapy (PSORT) consortium, we assessed ‘real‐world’ levels of self‐reported 
nonadherence to conventional and biological systemic therapies and evaluated 
psychological and biomedical factors associated with nonadherence using 
multivariable analyses. Cross‐sectional data from 811 patients with moderate‐to‐
severe psoriasis using a conventional systemic (35.3%) or biological therapy (64.7%) 
were collected from 35 dermatology centres across England. All patients were 
enrolled in the British Association of Dermatologists Biologic Interventions Register 
(BADBIR). A questionnaire assessed patients’ illness and medication beliefs 
(Revised Illness Perception Questionnaire and Beliefs about Medicines 
Questionnaire), psychological distress (Hospital Anxiety and Depression Scale), the 
strength of the patient's routine or habit for using their medication (Self‐Reported 
Habit Index) and medication adherence (Medication Adherence Report Scale, 
MARS), with a score ≤ 38 out of 40 on the MARS indicating nonadherence. Patients’ 
biomedical data were obtained from the registry. A significant proportion of patients 
using conventional systemic (methotrexate, ciclosporin, acitretin, fumaric acid esters) 
or biological therapies (etanercept, adalimumab) were classified as nonadherent 
(22.4%); 12% were intentionally nonadherent, such as deliberately altering the dose, 
timing or frequency of their therapy, and were 10.9% unintentionally nonadherent, 
such as forgetting to use their therapy. Only 7.3% of patients using ustekinumab 
were classified as nonadherent. Patients using a conventional systemic were 
significantly more likely to be classified as nonadherent compared with those using 
etanercept or adalimumab (29.2% vs. 16.4%; P ≤ 0.001). After accounting for 
relevant variables, patients who expressed the strongest concerns about their 
systemic therapy and medicines in general were significantly more likely to be 
classified as intentionally nonadherent (odds ratio 2.27, 95% confidence interval 
1.16–4.47). Patients who reported weaker routine or habit for using their therapy 
were significantly more likely to be classified as unintentionally nonadherent (odds 
ratio 0.92, 95% confidence interval 0.89–0.96). Medication nonadherence needs to 
be assessed when determining factors influencing treatment response. Medication 
beliefs and habit strength are important modifiable targets for strategies to improve 
adherence and clinical outcomes in the management of psoriasis. C.E.M.G. is a 
National Institute for Health Research Senior Investigator. PSORT is funded by the 
Medical Research Council, grant MR/1011808/1. 
 
